Premium
Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients
Author(s) -
Davies J.,
Gavin A.,
Band M.,
Morris A.,
Struthers A.
Publication year - 2005
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2005.02363.x
Subject(s) - spironolactone , pulse wave velocity , medicine , cardiology , blood pressure , crossover study , placebo , arterial stiffness , brachial artery , endocrinology , type 2 diabetes , diabetes mellitus , heart failure , alternative medicine , pathology
Aims To assess whether spironolactone has beneficial effects on blood pressure (BP), N‐terminal propeptide of type III procollagen (PIIINP) and pulse wave velocity (PWV) in hypertensive, type II diabetics. Methods Ten patients with type II diabetes and hypertension were enrolled in a randomized, double‐blind crossover study comparing 4 months’ treatment with spironolactone and placebo with a 4‐week washout phase. BP, PIIINP and carotid‐radial PWV were measured at the end of each treatment phase. Results Compared with placebo, spironolactone reduced systolic BP by 15.6 ± 46.1 mmHg ( P = 0.005, 95% CI 2.7–28.5 mmHg), PIIINP by 0.6 ± 0.3 µg l −1 ( P = 0.04, 95% CI 0.02–1.1 µg l −1 ) and PWV by 0.6 ± 0.2 m s −1 ( P = 0.008, 95% CI 0.18–1.02 m s −1 ). Conclusions Spironolactone is effective at reducing systolic BP and brachial artery stiffness as indicated by PWV. It also reduces PIIINP in type II diabetic patients with hypertension.